



I hereby certify that this correspondence was deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on October 31, 2002

Caroline Weiberk 45,203
 Attorney/Agent Registration No.
Caroline Weiberk
 Signature of Attorney

3761
\$

IN THE UNITED STATES PATENT & TRADEMARK OFFICE
 RESPONSE/AMENDMENT

Case Docket No. 7042R

Box Non-Fee Amendment
 ASSISTANT COMMISSIONER FOR PATENTS
 Washington, D.C. 20231

Dear Sir:

Transmitted herewith is a RESPONSE for the patent application:

Inventor(s): Rourke, et al. Confirmation No. 9622
 Serial No.: 09/529,575 Group Art Unit: 3761
 Date Filed: July 13, 2001 Examiner: J. Webb
 Title: PROTEASE INHIBITORS IN ABSORBENT ARTICLES

RECEIVED
 NOV 12 2002

TECHNOLOGY CENTER R3700

- No additional fee is known to be required.
- The fee has been calculated as shown below:

	(Col. 1)		(Col. 2)	(Col. 3)	OTHER THAN A SMALL ENTITY	
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA*	RATE	FEE'
TOTAL	* 16	MINUS	** 20	= 0	x \$18 =	\$0.00
INDEP.	* 1	MINUS	*** 5	= 0	x \$84 =	\$0.00
FIRST PRESENTATION OF MULTIPLE DEP. CLAIM					+ \$280 =	\$0.00
					TOTAL	\$0.00

* If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.
 ** If the highest number of total claims previously paid for is less than 20, write "20" in this space.
 *** If the highest number of independent claims previously paid for is less than 3, write "3" in this space.
 The "Highest Number Previously Paid For" (Total or Independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment or the number of claims originally filed.

- The Commissioner is hereby petitioned under 37 CFR §1.136(a) to grant any extension of time needed for timely response to the Office Action dated June 7, 2002 in the above-identified application to preserve pendency of said application. The processing fee under 37 CFR §1.17 has been determined as follows: \$400.00 for a two-month extension of time.
- The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 16-2480. A duplicate copy of this sheet is attached.
 - Any patent application processing fees under 37 CFR §1.16.
 - Any patent application processing fees under 37 CFR §1.17.
- The Commissioner is hereby authorized to make any additional copies of this sheet needed to accomplish the purposes provided for herein and to charge any fee for such copies to Deposit Account No. 16-2480.

Caroline Weiberk
 Caroline Weiberk
 Attorney or Agent for Applicant(s)
 Registration No. 45,203
 Tel. No. (513) 626-1139

Date: October 31, 2002
 Customer No. 27752
 (last revised 7/1/02)



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner For Patents, Washington, D.C. 20231 on October 31, 2002

16/C
B. Webb
11/13/02

CAROLINE WEL-BERK 45,203
Name of Attorney Filing Document Reg. No.
Caroline Wel-Berk
Signature of Attorney Mailing Document

Case 7042R

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of
Rourke et al. :
Serial No. 09/529,575 : Group Art Unit:3761
Filed: July 13, 2001 : Examiner: J. Webb
Confirmation No.: 9622

Title: PROTEASE INHIBITORS IN ABSORBENT ARTICLES

RECEIVED

NOV 12 2002

RESPONSE TO OFFICE ACTION

The Assistant Commissioner for Patents
Washington, D.C. 20231

TECHNOLOGY CENTER R3700

Dear Sir:

This is fully responsive to the Office Action dated June 7, 2002. Applicants respectfully request the Examiner to consider the present application in view of the amendments, the remarks and the accompanying Declaration by Dr. Scott Edward Osborne submitted pursuant to 37 C. F. R. §1.132.

Also included herewith is a new formal drawing, in response to the Examiner's objection.

A two-months extension is respectfully requested pursuant to 37 C. F. R §1.136(a).

AMENDMENTS

IN THE SPECIFICATION

On page 6, please amend "BRIEF DESCRIPTION OF THE DRAWINGS" as indicated.

Figure 1 is a schematic illustration of an absorbent article in the form of a diaper according to the present invention.

Figure 2A is a side view showing placement of a skin analog used in the skin care composition transfer test and/or the protease inhibitor transfer test.

C1

Figure 2B is a plan view showing placement of the skin analog used in the skin care composition transfer test and/or the protease inhibitor transfer test.

Figure 3 is an absorbent article in the form of a diaper, which has a plurality of lotion stripes.